Tag: Andrew Percy

The below Parliamentary question was asked by Andrew Percy on 2016-02-09.

To ask the Secretary of State for Health, what assessment he has made of the implications for his policies on the use of the Mental Health Act 1983 are of the Care Quality Commission’s sixth annual report, HC483, published on 14 October 2015.

Alistair Burt

The Mental Health Act 1983: Code of Practice, which came into force in April 2015, provides statutory guidance on how functions under the Mental Health Act 1983 (the Act) should be carried out. All providers of mental health services under the Act have a duty to abide by both the provisions of the Act and the detailed guidance on how implement those provisions contained in the Code of Practice. That includes the duty of all such mental health providers to ensure their staff know and understand their responsibilities under the Act.

Empowerment and the involvement of patients are key principles underpinning the Act, and the Code of Practice is clear that detained patients must be informed of their rights; that it is the responsibility of those treating them to ensure that patients understand their rights; and that patients are aware that they are entitled to ask for the assistance of an Independent Mental Health Advocate (IMHA) to help them understand this information.

The Care Quality Commission’s (CQC) annual report Monitoring the Mental Health Act 2014/15 indicates that CQC have already taken action where providers are failing to effectively monitor the Act, train staff and support patients and recommends that services use the findings of that report to make sure staff have the right skills and knowledge and decide what action needs to be taken to improve the care and support available for patients.

The below Parliamentary question was asked by Andrew Percy on 2016-02-24.

To ask the Secretary of State for Health, what assessment he has made of the Alzheimer’s Society’s Fix Dementia Care campaign.

Jane Ellison

NHS England welcomes the campaign and its efforts to highlight areas in the health and care system where there is still room for improvement in the care of people with dementia. NHS England has already undertaken a range of initiatives to encourage hospitals to improve the standards of care provided to people living with dementia as well as their carers but recognises that more needs to be done.

Improving the care and support for people with dementia is a priority for this Government. That is why on 21 February 2015, the Prime Minister launched his Challenge on Dementia 2020 (PM Challenge 2020) to build on the progress of the Prime Minister’s Challenge on Dementia 2012-2015. It sets out the broad vision for dementia care, support, awareness and research to 2020.

The Department will soon publish an Implementation Plan which has been co-produced with key partners including the Alzheimer’s Society and sets out the actions partners across health and care will take to ensure commitments in the PM Challenge 2020 are delivered.

The below Parliamentary question was asked by Andrew Percy on 2016-02-24.

To ask the Secretary of State for Transport, what discussions his Department has had with the Department for Business, Innovation and Skills about the effect of bus franchising in the vehicle manufacturing sector.

Andrew Jones

I refer my hon Friend the Member for Brigg and Goole to the answer I gave on 15^th February, to Question UIN 26533.

“

The below Parliamentary question was asked by Andrew Percy on 2016-03-07.

To ask the Secretary of State for Business, Innovation and Skills, what steps he is taking to reduce the burden of EU regulation on businesses.

Anna Soubry

The February 2016 EU Reform settlement, secured by my right hon. Friend the Prime Minister, sets out concrete steps to reduce the burden of EU regulation on business. These include regulatory simplification (including the withdrawal or repeal of legislation); a specific focus on reducing the burden on SMEs and micro-enterprises; and establishing burden reduction targets in the most onerous areas for business.

We will now work with Member States to hold the EU institutions to account, overseeing the agreement and implementation of these measures.

The below Parliamentary question was asked by Andrew Percy on 2016-03-24.

To ask the Secretary of State for Health, whether his Department plans to use the inflammatory bowel disease (IBD) registry to get an accurate number of people living with IBD.

Jane Ellison

The IBD (inflammatory bowel disease) Registry provides a United Kingdom-wide repository of anonymised IBD adult and paediatric patient data for prospective audit and research purposes. Patients must consent for their data to be added to the registry. The Healthcare Quality Improvement Partnership (HQIP) has allocated transitional funding this year to incorporate IBD audit data collection into the IBD Registry, providing an enhanced system for data capture and quality improvement that will be available to every hospital in the UK. This will allow the entry of data locally and support service improvement. Initially the focus will be for IBD patients receiving biologic treatments, but the system will address other key aspects of IBD care in the future.

The second step of data collection will be to focus on new patients with IBD to begin to understand the incidence of IBD in the UK. This picture will build up over a number of years and be dependent on the engagement of clinicians.

No specific assessment of the potential effects on healthcare due to the introduction of a registry of patients with IBD in England has been made. However, the data provided through the register can support National Health Service services in areas such as the assessment of local IBD populations as well as in measuring incidence and outcomes with services in other parts of the UK.

Although there is no direct Department funding, HQIP have given £290,000 for a year’s transition funding to join the audit data with the registry.

The National Institute for Health and Care Excellence (NICE) recommends faecal calprotectin testing as an option to help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome.

The NICE IBD Quality Standard states that general practitioners (GP) and GP practices should ensure that testing is offered and clinical commissioning groups should ensure the diagnostic services are in place to support this.

The below Parliamentary question was asked by Andrew Percy on 2016-05-23.

To ask the Secretary of State for Health, how many people with (a) Crohn’s disease and (b) ulcerative colitis have been treated with biological drugs in each of the last five years.

George Freeman

The National Institute for Health and Care Excellence (NICE) has recommended four different biological drugs for the treatment of inflammatory bowel disease (IBD), the collective term for Crohn’s disease and colitis, for use after the failure of conventional therapies or in patients for whom such therapies are not appropriate. The National Health Service is legally obliged to fund medicines and treatments recommended by NICE’s technology appraisals.

Although information concerning the exact number of people with IBD who have been treated with biological drugs in each of the last five years is not available, and no specific assessment of access has been made, some data are collected as part of the IBD audit. The IBD audit programme is commissioned by the Healthcare Quality Improvement Partnership on behalf of NHS England and Wales (with additional funding from Healthcare Improvement Scotland), as part of the National Clinical Audit and Patient Outcomes Programme, and carried out by the Royal College of Physicians.

The biological therapies part of the IBD audit aims to assess nationally: the efficacy of biological therapies in the treatment of IBD; the safety of biological therapies in the treatment of IBD; and IBD patients’ views on their quality of life at defined intervals throughout their use of biological therapies. The latest round of audit findings, published in September 2015, showed treatment continued to be effective and that patients were receiving treatment with biological therapies at earlier stages of disease. More information can be found at the following link:

www.rcplondon.ac.uk/projects/ibd-biological-therapy-audit

“

The below Parliamentary question was asked by Andrew Percy on 2016-07-06.

To ask the Secretary of State for Business, Energy and Industrial Strategy, what the timetable is for publishing the Government’s analysis of whole system costs.

Mr Nick Hurd

Following peer review by experts in the field of whole system impacts, the Department for Business, Energy and Industrial Strategy will publish the methodology report of the Whole System Impacts of Electricity Generation Technologies project in due course.

The below Parliamentary question was asked by Andrew Percy on 2015-10-27.

To ask the Secretary of State for Health, what assessment he has made of the time taken to decide on patient access scheme applications for drugs through the Cancer Drugs Fund.

George Freeman

Within the framework set out in the 2014 Pharmaceutical Price Regulation Scheme, a Patient Access Scheme (PAS) can be proposed by a pharmaceutical company and agreed by the Department to improve the cost-effectiveness of a medicine as part of a National Institute for Health and Care Excellence (NICE) technology appraisal.

A PAS proposal can only be submitted for a medicine that is available through the Cancer Drugs Fund if that product is also scheduled for appraisal or review by NICE and no assessment has been of the time taken to consider any such PAS proposals.

The below Parliamentary question was asked by Andrew Percy on 2015-10-26.

To ask the Secretary of State for Education, how many defibrillators have been purchased by new schools nationally in accordance with guidance issued in 2014 by her Department; and what assessment she has made of the effect of this guidance.

Edward Timpson

The Department does not hold information on the number of schools which have staff trained in CPR. All schools should have at least one first-aider, and the number of first-aid personnel will be based on local circumstances, considered as part of a first aid needs assessment in the school. Recognised certificated courses ‘First Aid at Work’ or ‘Emergency First Aid at Work’ train staff in the administration of CPR.

The guidance published by the Department in November 2014 promoted a scheme to enable schools to purchase defibrillators at reduced cost. As of 23 October 2015, 735 defibrillators had been purchased by schools through this scheme. The Department does not hold information on the total number of schools with a defibrillator.

The below Parliamentary question was asked by Andrew Percy on 2015-10-26.

To ask the Secretary of State for Education, how many schools in England have (a) staff trained in CPR or (b) a defibrillator on site; and what plans her Department has to ensure that all schools have (i) such staff and (ii) on-site defibrillators.

Edward Timpson

The Department does not hold information on the number of schools which have staff trained in CPR. All schools should have at least one first-aider, and the number of first-aid personnel will be based on local circumstances, considered as part of a first aid needs assessment in the school. Recognised certificated courses ‘First Aid at Work’ or ‘Emergency First Aid at Work’ train staff in the administration of CPR.

The guidance published by the Department in November 2014 promoted a scheme to enable schools to purchase defibrillators at reduced cost. As of 23 October 2015, 735 defibrillators had been purchased by schools through this scheme. The Department does not hold information on the total number of schools with a defibrillator.